MNTA stock forecast
Our latest prediction for Momenta Pharmaceuticals, Inc.'s stock price was made on the Feb. 11, 2020 when the stock price was at 31.75$.
In the short term (2weeks), MNTA's stock price should underperform the market by -2.68%. During that period the price should oscillate between -9.36% and +7.60%.
In the medium term (3months), MNTA's stock price should underperform the market by -8.12%. During that period the price should oscillate between -33.04% and +18.00%.Get email alerts
About Momenta Pharmaceuticals, Inc.
Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA.
At the moment the company generates 59M USD in revenues.
On its last earning announcement, the company reported a loss of -2.12$ per share.
The book value per share is 3.60$
Three months stock forecastFeb. 11, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|